FDA Approval Secured for Preservative-Free Ketamine: NRx Pharmaceuticals Expands Market Opportunity

Uniting the World: Global Psychedelic Week 2025

Advancements and Milestones in Neuropsychiatry Drug Development by Cybin Inc.

Fireside Chat at TD Cowen's Summit with Cybin Inc. Executives

Advancements in Mental Health Treatments: NRx Pharmaceuticals and Cybin Inc. Acquisitions and Developments

Cybin Inc. Chief Business Officer to Speak at H.C. Wainwright Conference

Fireside Chat with Cybin Inc.'s CMO at Cantor Global Healthcare Conference

Leadership Changes and Treatment Advancements in Mental Health Companies

Advancing Psilocybin Therapy: Psylutions Supports Rescheduling Efforts

Empowering Growth for Ketamine & TMS Clinics: Strategic Partnership Announcement

Cybin Inc. Receives Approval for Phase 3 Study of CYB003 in Australia

NRx Pharmaceuticals Urges FDA to Ban Benzethonium Chloride from Ketamine Products

Advancements in Incannex Healthcare Inc.: Positive Phase 2 Results and Strong Valuation Potential

Cybin Inc. Reports Promising Results and Shareholder Meeting Summary

Cybin Inc. Reports Q1 2025 Results and Progress in Depression and Anxiety Studies

NRx Pharmaceuticals' HOPE Therapeutics(TM) Expands Network and Expertise with Acquisition of Dura Medical LLC

Cybin Inc. Receives European Approval for Phase 3 Study on CYB003 for Major Depressive Disorder

Revolutionizing Mental Healthcare: Cybin's CEO to Speak at Growth Conference

Exploring Neuroplasticity in CNS Disorders with NRx Pharmaceuticals CEO

Cybin Inc. Receives UK Approval for Phase 3 Trial in Depression